Intracellular mGluR5 plays a critical role in neuropathic pain

Metabotropic glutamate receptor 5 (mGluR5) is well-established as a mediator of persistent pain within the spinal cord, but the specific location of the functional receptor pool—cell surface versus intracellular membranes—has remained unclear. Given that intracellular GPCRs often trigger distinct signaling pathways from their surface counterparts, this study investigated the subcellular distribution and functional role of mGluR5 in spinal dorsal horn (SCDH) neurons. Using electron microscopy, immunocytochemistry, subcellular fractionation, and calcium imaging, the authors assessed how nerve injury (specifically the spared-nerve injury model) alters the localization and signaling of mGluR5. They further utilized membrane-permeable and impermeable pharmacological agents, alongside inhibitors of glutamate transporters, to differentiate between the physiological impacts of surface versus intracellular receptor activation on pain behaviors.

The researchers discovered that over 80% of mGluR5 in SCDH neurons is located intracellularly, with a significant proportion residing on the nuclear membrane. This nuclear pool is functionally active; when activated by glutamate—delivered intracellularly via excitatory amino-acid transporters (EAATs)—it initiates sustained nuclear calcium responses. Following nerve injury, the expression of this nuclear mGluR5 increases significantly, as do associated downstream signaling markers like pERK1/2 and Arc/Arg3.1. Crucially, the study demonstrated that intrathecal administration of a cell-permeable mGluR5 antagonist (fenobam) successfully relieved neuropathic pain and reduced c-fos expression in injured rats, while an impermeable antagonist had minimal effects. Finally, blocking neuronal glutamate uptake (EAAT3 inhibition) mimicked the analgesic effects of the permeable mGluR5 antagonist, confirming that the intracellular receptor pool is a critical driver of the pathological pain state.

This paper provides the first in vivo behavioral evidence that an intracellular GPCR can modulate complex physiological phenotypes. It challenges the conventional view that GPCR-mediated pain signaling is exclusively a cell-surface phenomenon. By establishing intracellular mGluR5 as a key therapeutic target for neuropathic pain, the research provides a biological basis for why many previous mGluR5-targeting drugs may have shown inconsistent efficacy. These findings offer a new strategy for developing pain therapies that specifically target these internalized receptor pools.